This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look at the updated safety, efficacy and PK data from the on-going APEX-01 trial of ARX517 in patients with mCRPC.
Ticker(s): JNJ, AMAMWho's the expert?
Institution: Self-employed
- Board Certified Hematologist and Medical Oncologist in private practice since 2011
- treats 25 patients for B-Cell Non-Hodgkin’s Lymphoma, 10 of whom have the diffuse large B-cell lymphoma (DLBCL) subtype
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
